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Abstract: Corticosteroids (CS) effects on insulin resistance related genes in rat skeletal muscle were studied. In our acute 
study, adrenalectomized (ADX) rats were given single doses of 50 mg/kg methylprednisolone (MPL) intravenously. In our 
chronic study, ADX rats were implanted with Alzet mini-pumps giving zero-order release rates of 0.3 mg/kg/h MPL and 
sacriﬁ  ced at various times up to 7 days. Total RNA was extracted from gastrocnemius muscles and hybridized to Affymetrix 
GeneChips. Data mining and literature searches identiﬁ  ed 6 insulin resistance related genes which exhibited complex 
regulatory pathways. Insulin receptor substrate-1 (IRS-1), uncoupling protein 3 (UCP3), pyruvate dehydrogenase kinase 
isoenzyme 4 (PDK4), fatty acid translocase (FAT) and glycerol-3-phosphate acyltransferase (GPAT) dynamic proﬁ  les were 
modeled with mutual effects by calculated nuclear drug-receptor complex (DR(N)) and transcription factors. The oscillatory 
feature of endothelin-1 (ET-1) expression was depicted by a negative feedback loop. These integrated models provide test-
able quantitative hypotheses for these regulatory cascades.
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Introduction
A major function of the hypothalmic/pituitary/adrenal axis (HPA-axis) involves regulating the production, 
storage, use, and distribution of substrates for systemic energy metabolism. Glucocorticoids, the effecter 
hormones from the adrenal gland, were named for their glucose-regulating properties and have exten-
sive impact on carbohydrate, lipid, and protein metabolism. Glucocorticoids are the major regulators 
of systemic gluconeogenesis, a multi-tissue phenomena involving substrate ﬂ  ow from muscle and fat 
coupled with enzymatic synthesis of glucose from these substrates in liver and kidney. Glucocorticoid 
output from the adrenal cortex, which occurs with a circadian periodicity, serves to maintain adequate 
blood glucose in order to assure that sufﬁ  cient glucose is available to fulﬁ  ll the needs of vital organs, 
particularly the brain. This is accomplished by adjusting both supply and demand. On the supply side, 
glucocorticoids increase the synthesis and activity of enzymes in the gluconeogenic pathway in liver 
and kidney, as well as ancillary enzymes/pathways such as expression of aminotransferases and com-
ponents of the urea cycle. They also control the release of gluconeogenic substrates from muscle and 
fat. On the demand side, they decrease glucose utilization in peripheral tissues which in part encom-
passes their anti-inﬂ  ammatory and immunosuppressive actions.
Synthetic glucocorticoids, corticosteroids (CS), are used therapeutically for a wide variety of con-
ditions that require immune and/or inﬂ  ammatory modulation. Because corticosteroids pharmacologi-
cally magnify the physiological actions of glucocorticoids, therapeutic use of this class of drugs is 
accompanied by a wide range of adverse effects that include muscle wasting and hyperglycemia. 
Skeletal muscle is the major organ responsible for glucose disposal, accounting for about 80% of total 
glucose uptake under insulin stimulation. Corticosteroids exert their glucose sparing effect on skeletal 
muscle mainly by inhibiting glucose utilization and switching muscle energy metabolism from glucose 
to lipids. Inhibition of insulin-directed glucose disposal in skeletal muscle in conjunction with enhanced 
gluconeogenesis results in elevated plasma glucose levels (diabetes). In addition, prolonged exposure 142
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to corticosteroids and the attendant net degradation 
of muscle protein causes atrophy of the muscula-
ture.
Previously, we used a rat model and employed 
Affymetrix gene arrays to proﬁ  le the time course 
of changes in gene expression in skeletal muscle 
of male rats in response to a single bolus dose of 
the synthetic corticosteroid, methylprednisolone 
(MPL). ADX animals were used to eliminate cir-
cadian oscillation in corticosteroid responsive 
genes, which facilitated data mining. This time 
course involved 16 time points over a 72 hour 
period plus untreated controls. Because these 
experiments were initiated using adrenalectomized 
animals, the drug in effect acted as a stimulus that 
perturbed the homeostatic balance of the system, 
and the experiment monitored the deviation of the 
system and its return to the original state. The 
objective was to identify those changes in tran-
scription induced by corticosteroids, which if 
perpetuated by repeated dosing, would manifest as 
chronic adverse effects. Using a ﬁ  ltering approach 
to eliminate unregulated probe sets, we identiﬁ  ed 
653 probe sets out of 8799 with a high probability 
of being regulated (Almon et al. 2004). Of these, 
we identiﬁ  ed 29 probe sets (representing 22 gene 
transcripts) directly related to insulin resistance 
(Almon et al. 2005b).
Although very useful, a single time series only 
provides a one dimensional view of the dynamics 
of the system in response to the stimulus. A phar-
macological time series is different from most time 
series studies (for example those assessing devel-
opmental changes) in that it can be challenged 
using a different dosing regimen. A second dosing 
regimen is valuable in two regards. First, it can 
serve to corroborate results of the ﬁ  rst dosing 
regimen. If changes in expression levels for a par-
ticular transcript are observed in multiple time 
points and in multiple animals from two different 
doses, these changes are unlikely to result from 
chip artifacts. Second, the results can be used to 
group genes with common mechanisms of regula-
tion. If two or more genes have a common mech-
anism of regulation, then their response proﬁ  les 
should follow the same pattern regardless of the 
dosing regimen. More recently, we used microar-
rays to broadly characterize the response of skel-
etal muscle to a second dosing regimen which 
entailed chronic infusion of MPL in a group of 
ADX male rats. For these experiments MPL was 
infused at 0.3 mg/kg/h for 168 hours using 
Alzet osmotic pumps. Four animals were sacriﬁ  ced 
at each of ten different times during the infusion 
period. Here the drug essentially was used as an 
unbalancing stimulus and the experiment evaluated 
the capacity of the system to rebalance in the con-
tinuous presence of the drug.
Microarrays provide a method of high through-
put data collection that is necessary for construct-
ing comprehensive information on the transcriptional 
basis of such complex systemic polygenic phe-
nomena as insulin resistance. When microarrays 
are used in rich in vivo time series studies they 
yield temporal patterns of changes in gene expres-
sion that illustrate the cascade of molecular events 
in time that cause complex responses. With such 
data, the challenge then becomes one of construct-
ing rational, quantitative, mechanism-based frame-
works that describe the relationships between the 
elements of the cascades. Kinetic/dynamic model-
ing provides an approach to developing quantita-
tive, testable, mechanism-based hypotheses 
concerning the relationship between drug kinetics 
and elements of cascades that continue long after 
the drug has dissipated. Such models can accom-
modate hierarchal cascades where one process 
generates molecules that become effectors or 
mediators for other processes. They can also 
accommodate convergence of cascades that com-
monly occur in the control of the expression of 
genes where binding sites for multiple nuclear 
factors participate in the regulation of the level of 
expression of a particular mRNA. Proteins (tran-
scription factors) expressed from this mRNA in 
turn become endogenous mediators that may them-
selves become effector molecules for other pro-
cesses.
In the present report we use the two response 
proﬁ  les (acute and chronic) to develop kinetic/
dynamic models for the regulation of the expres-
sion of six genes that contribute to corticosteroid 
induced insulin resistance in skeletal muscle. The 
ﬁ  rst is insulin receptor substrate-1 (IRS-1). Here 
we model the expression proﬁ  le as being driven 
by both MPL and Interleukin 6 (IL-6). The second 
and third are two nuclear encoded mitochondrial 
genes with similar expression proﬁ  les, uncoupling 
protein 3 (UPC3) and pyruvate dehydrogenase 
kinase isoenzyme 4 (PDK4). These two genes are 
modeled as being driven by both MPL and the 
muscle speciﬁ  c transcription factor MyoD. The 
fourth and fifth are two genes related to the 
increased use of lipids for energy, fatty acid 143
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translocase (FAT) and glycerol-3-phosphate 
acyltransferase (GPAT). These two genes are mod-
eled as being under the combined inﬂ  uence of both 
MPL and sterol regulatory element binding 
protein-1c (SREBP-1c). The last is endothelin-1 
(ET-1) which inﬂ  uences vascular resistance in 
skeletal muscle, thereby inﬂ  uencing both blood 
ﬂ  ow and glucose disposal. Although these are four 
separate models, they represent a beginning at 
developing more comprehensive models for the 
complex phenomena of glucocorticoid-induced 
insulin resistance in skeletal muscle. Such models 
gain more importance when the data linking glu-
cocorticoids to the insulin resistance associated 
with metabolic syndrome are considered.
Materials and Methods
Experimental
Gastrocnemius muscles were obtained from animal 
studies performed in our laboratory (Sun et al. 
1999; Ramakrishnan et al. 2002). In the acute 
study, male ADX Wistar rats weighing 225–250 g 
(Harlan Spague-Dawley Inc., IN) were subject to 
right external jugular vein cannulation under light 
ether anesthesia one day prior to the study. A single 
intravenous bolus of 50 mg/kg MPL (Solu-Medrol, 
Pharmacia-Upjohn Company, MI) was given to 47 
animals via right jugular vein cannula. Rats were 
sacriﬁ  ced by aortic exsanguination at 0.25, 0.5, 
0.75, 1, 2, 4, 5, 5.5, 6, 7, 8, 12, 18, 30, 48 and 72 h 
after dosing. The sampling time points were 
selected based on previous studies of receptor 
dynamics and enzyme induction in muscle and 
liver (Sun et al. 1998; Sun et al. 1999; Ramakrish-
nan et al. 2002). Four vehicle-treated rats were 
designated as controls and were considered as 
sacriﬁ  ced at time point zero. In a companion study, 
6 animals were treated with single intravenous 
bolus of 50 mg/kg MPL. Blood samples were taken 
serially from the cannula at 0.5, 1, 2, 4, 5, 6, 8, 10, 
12, 24, 36, 48 and 72 h. Blood samples were stored 
at −80 °C and were used to determine plasma MPL 
concentrations. In our chronic study, 40 male ADX 
Wistar rats weighing 300–350 g were given 
0.3 mg/kg/h infusions of MPL reconstituted in 
supplied diluent. The infusions were given using 
Alzet osmotic pumps (Model, 2001, ﬂ  ow rate 
1 ul/h; Alza, Palo Alto, CA). The pump drug solu-
tions were prepared for each rat based on its pre-
dose body weight. Pumps were subcutaneously 
implanted between the shoulder blades on the back. 
Four rats were sacriﬁ  ced by aortic exsanguination 
at 6, 10, 13, 18, 24, 36, 48, 72, 96, and 168 h. Four 
control rats were implanted with a saline-ﬁ  lled 
pump and sacriﬁ  ced at various times throughout 
the 7-day study period. Gastrocnemius muscles 
were rapidly excised, quickly frozen in liquid 
nitrogen, and stored at −80 °C.
Drug assay
MPL plasma concentrations were measured by a 
previously described normal-phase high performance 
liquid chromatography (HPLC) method (Haughey 
and Jusko, 1988). The quantitation limit of this 
method is 10 ng/ml.
RNA extraction
Frozen gastrocnemius muscles were ground into 
powder using a mortar and pestle chilled with 
liquid nitrogen. Total RNA extractions were carried 
out by a Trizol-chloroform based extraction 
method. About 100 mg muscle powder from each 
animal was added to prechilled Trizol Reagent 
(Invitrogen, Carlsbad, CA) at a ratio of tissue:
Trizol of 1:10. Extractions were performed 
according to manufacturer protocols. Extracted 
RNA was further puriﬁ  ed by passage through 
RNUeasy mini-columns (Qiagen, Valencia, CA). 
Final extracted RNA samples were resuspended in 
nuclease-free water. Quantity of total RNA was 
determined by spectrophotometry and purity was 
assessed by agarose gel electrophoresis. Extracted 
total RNA preparations were stored at −80 °C.
Microarrays
Isolated muscle RNA from each individual animal 
was used to prepare biotinylated cRNA target 
according to manufacturer protocols. Then bioti-
nylated cRNAs from the acute study were 
hybridized to 51 individual Affymetrix GeneChip
® 
Rat Genome U34A (Affymetrix, Santa Clara, CA), 
which contained 8799 probe sets. The target 
cRNAs from the chronic study were hybridized to 
44 individual Affymetrix GeneChip
® Rat Genome 
230A (Affymetrix, Santa Clara, CA), which 
contained 15967 probe sets. Oligonucleotide 
microarrays were utilized because of their high 
reproducibility between separate arrays. Both 
datasets have been submitted to the National Center 
for Biotechnology Information (NCBI) Gene 144
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Expression Omnibus database (GSE490 and 
GSE5101) and are also available online at http://
pepr.cnmcresearch.org/ (Almon et al. 2003). Our 
approach to identifying probes of interest has been 
described in previously published articles on min-
ing the datasets for muscle, liver and kidney from 
the acute MPL treated animals (Almon et al. 2004; 
Almon et al. 2005a; Almon et al. 2005c). Literature 
searches of the 653 probe sets identiﬁ  ed in the acute 
skeletal muscle dataset yielded 29 probe sets rep-
resenting 22 genes whose expression is related to 
insulin resistance in skeletal muscles (Almon et al. 
2005b). Sufﬁ  cient information from our own work 
and from the literature allowed us to develop four 
rational mechanistic models describing the regula-
tion of the expression of six genes related to insu-
lin resistance. Data from both acute and chronic 
studies were simultaneously modeled.
Dynamic Modeling
Kinetics
The kinetics of plasma MPL following intravenous 
drug injection and infusion was described by a 
two-compartment model with a zero-order input 
k0 into the central compartment.
 
dA
dt
kkA kA
CL
V
A
p
tp
p
p =+⋅−⋅−
⎛
⎝
⎜
⎞
⎠
⎟ ⋅ 02 1 1 2  (1)
dA
dt
kAkA AC V
t
pt p p p =⋅−⋅ =⋅ 12 21 where  (2)
where Ap and At are the drug amounts in the plasma 
and tissue compartments and CL, Vp, k12 and k21 
are clearance, central compartment volume of 
distribution, and distribution rate constants. These 
parameters were ﬁ  xed according to previous lit-
erature values (Sun et al. 1999).
Receptor dynamics
Glucocorticoid receptor dynamics in skeletal 
muscle following single intravenous 50 mg/kg 
MPL treatment was previously described 
by a mechanistic receptor-gene mediated 
pharmacodynamic model (Fig. 1) (Sun et al. 1999). 
The model was developed using the assumption 
that unbound MPL molecules diffuse through cell 
membranes and bind with cytosolic free receptors. 
Drug-receptor complex is translocated into the 
nucleus where it dimerizes and binds to glucocor-
ticoid response elements (GREs) in the target 
DNA. The binding of drug-receptor complex to 
GREs enhances or inhibits the expression of target 
genes. Corticosteroids are known to inhibit the 
expression of their own receptors (Dong et al. 
1988). After dissociation from DNA, GR receptors 
are recycled into cytosol, where part of receptors 
are degraded and the rest may be further activated 
by MPL (Sun et al. 1999). The equations describing 
the model are:
Figure 1. Fifth-generation CS pharmacodynamic model of receptor-gene mediated effects. Symbols and differential equations are deﬁ  ned in 
Eq. 3 to 8 and Table 1. The solid rectangle represents inhibition of glucocorticoid receptor transcription by DR(N) via an indirect mechanism.145
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where symbols represent cytosolic free glucocor-
ticoid receptor density (GR), GR mRNA (GRmRNA), 
cytosolic GR-drug complex (DR), GR-drug com-
plex in nucleus (DR(N)), zero-order GR mRNA 
synthesis rate constant (ks_Rm), and ﬁ  rst-order rate 
constants for GR mRNA degradation (kd_Rm), GR 
synthesis (ks_R) and GR degradation (kd_R). Other 
rate constants include: second-order association 
rate constant of GR and drug (kon), translocation 
rate constant of DR from cytosol to nucleus (kT), 
and the overall turnover rate of DR(N) (kre). The 
fraction of GR that is recycled from nucleus to 
cytosol (Rf) can be further activated by association 
of drug. Thus (1-Rf) is the fraction of GR that is 
degraded during one cycle of drug-receptor 
complex translocation. The IC50_Rm is the 
concentration of DR(N) at which the synthesis 
rate of GR mRNA is reduced to 50% of its 
baseline level.
Assuming the receptor system is at steady-
state before administration of MPL and there is 
no endogenous glucocorticoid present in ADX 
rats, the following conditions are derived from 
Eq. (3) and (4).
  kk G R sR m dR m m R N A __ =⋅
0
 (7)
  kk
GR
GR
sR dR
mRNA
__ =⋅
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where GR
0
mRNA and GR
0 are the baseline levels of 
GR mRNA and free cytosolic GR at time zero. In 
our previous study, these were measured in tissues 
from the same animals by quantitative Northern 
hybridization and [
3H]-dexamethasone ligand 
binding assays (Sun et al. 1999). In the present 
report, GR
0
mRNA and GR
0 were ﬁ  tted as well as other 
parameters in the receptor dynamics model. Values 
of DR
0 and DR(N)
0 were assumed to be zero in the 
absence of steroid. Parameters estimated from the 
modeling of acute data were used to simulate recep-
tor mRNA and receptor density proﬁ  les for the 
chronic study.
Insulin receptor substrate-1 (IRS-1)
IRS-1 belongs to the IRS family of adaptor proteins 
and is involved in insulin signaling. It has been 
reported that chronic CS treatment down-regulates 
the expression of IRS-1 in skeletal muscle 
(Giorgino et al. 1993). Additionally, interleukin 6 
(IL-6) exerts long-term inhibitory effects on the 
transcription of IRS-1 while IL-6 receptor expres-
sion is enhanced by CS treatment (Rotter et al. 
2003). A model is proposed according to these 
regulatory pathways (Fig. 2).
The equation describing the up-regulation of 
IL-6 receptor type 1 mRNA (IL6R1m) time proﬁ  le 
following MPL treatment is:
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where rate constants represent zero-order syn-
thesis rate (ks_IL6R1m) and ﬁ  rst-order degradation 
(kd_IL6R1m) of IL-6 receptor 1 mRNA. The 
enhancement of gene transcription is dependent 
on DR(N) with a maximum stimulatory effect 
(Smax_IL6R1m) and SC50_IL6R1m is the concentration 
of DR(N) that leads to 50% of maximum stimula-
tion of mRNA transcription. The baselines of 
IL6R1m were ﬁ  xed to 1 in the modeling for both 
acute and chronic studies.
The IRS-1 mRNA (mRNA) was described as:
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where symbols represent number of transit com-
partments (N), the nth transit compartment (TCn), 
the ﬁ  rst-order rate constant describing transit com-
partment turnover (ke), and the zero-order synthesis 
rate (ks_m) and ﬁ  rst-order degradation rate (kd_m) of 
mRNA. The IC50_DR(N) represents the concentration 
of DR(N) at which the production rate of mRNA 
is reduced to 50% of its baseline level under the 
inhibition of DR(N). The IC50_IL6R1 reﬂ  ects the 
concentration of TCn at which the production rate 
of mRNA is one-half of its baseline level when it 
is only inhibited by IL-6. Assuming steady-state at 
time zero, Eq. 12 allows calculation of:
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where TCn
0 is the baseline value of TCn and is 
ﬁ  xed as 1.
Uncoupling protein 3 (UPC3) and 
pyruvate dehydrogenase kinase 
isoenzyme 4 (PDK4)
Dexamethasone leads to increased expression of 
UCP3 in skeletal muscle in rats and mice (Gong 
et al. 1997; Sun et al. 2003). Similarly, PDK4 
mRNA and protein are augmented following dexa-
methasone treatment and are associated with 
decreased glucose oxidation rates (Qi et al. 2004). 
It has been reported that the expression of UCP3 
in muscle is enhanced by MyoD (Solanes et al. 
2000; Solanes et al. 2003). Examination of the 
promoter regions of both UCP3 and PDK4 reveals 
several GREs and MyoD binding sites that are 
conserved in several species. Models were thus 
proposed based on assumptions that both UCP3 
and PDK4 are regulated directly by CS and indi-
rectly by MyoD (Fig. 3). The equation describing 
MyoD mRNA (MyoDm) proﬁ  le is:
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Figure 2. Pharmacodynamic/pharmacogenomic model for CS effects on gene expression of IL-6 receptor 1 and IRS-1. Symbols and 
differential equations are deﬁ  ned in Eq. 9 to 13 and Table 2. The solid rectangle represents inhibition while the open rectangle represents 
stimulation in all diagrams.147
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where zero-order synthesis rate (ks_MyoDm) and ﬁ  rst-
order degradation rate constants (kd_MyoDm) of 
MyoD mRNA occur. An intermediate biosignal 
(BS) is described by a production and degradation 
rate constant of kBS (Jin et al. 2003). The inhibition 
of gene transcription is dependent on DR(N) and 
BS with inhibitory coefﬁ  cients (IC50_MyoDm and 
IC50_BS) reﬂ  ecting corresponding concentrations 
leading to 50% mRNA transcription reduction. The 
baselines of MyoDm in acute (BmRNAa_MyoD) and 
chronic (BmRNAc_MyoD) studies were estimated in 
the modeling.
dTC
dt
kM y o DB m R N A T C em a c M y o D
1
1 =⋅ − (/ ) () _  (16)
  dTC
dt
kT C T C
n
en n =⋅ − − () 1  (17)
The UCP3 mRNA (mRNA) time proﬁ  les were 
described as:
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The PDK4 mRNA (mRNA) time proﬁ  les were 
described as:
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where γMyoD is a power term representing the 
stimulatory efﬁ  ciency on UCP3 or PDK4 gene 
transcription by MyoD. The transcription of PDK4 
is dependent on DR(N) with a maximum stimula-
tory effect (Smax) and a stimulatory constant (SC50). 
For UCP3, assuming SC50 is much higher than 
DR(N) concentrations, Smax and SC50 are combined 
as one parameter SDR(N), which represents the linear 
coefﬁ  cient describing the stimulatory efﬁ  ciency of 
DR(N) on UCP3 mRNA production rate. Assuming 
steady-state at time zero, Eq. 18 and 19 allow 
calculation of:
  k
k
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sm
dm
n
MyoD _
_
()
=
0 γ  (20)
where TCn
0 is the baseline value of TCn and is 
ﬁ  xed as 1.
Fatty acid translocase (FAT) and 
glycerol-3-phosphate acyltransferase 
(GPAT)
These two genes are related to carbohydrate and 
lipid metabolism and are involved in insulin-
induced metabolic actions. They are all stimulated 
Figure 3. Pharmacodynamic/pharmacogenomic model for CS effects on gene expression of MyoD and its regulated genes. Symbols and 
differential equations are deﬁ  ned in Eq. 14 to 18 and Table 3.148
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by sterol regulatory element binding protein-1c 
(SREBP-1c) (Ericsson et al. 1997; Ntambi, 1999; 
Nguyen et al. 2000; Almon et al. 2005b). Models 
are proposed to describe their time proﬁ  les accord-
ing to underlying mechanisms (Fig. 4). The equa-
tions describing SREBP-1c mRNA (SREBPm) time 
proﬁ  le following MPL treatment are:
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where symbols represent zero-order synthesis rate 
(ks_SREBPm) and first-order degradation rate 
(kd_SREBPm) of SREBP-1c mRNA. The IC50_SREBPm 
and IC50_BS represent the concentrations of DR(N) 
and BS at which the corresponding production rates 
are reduced to 50% of baseline values. The base-
lines of SREBPm in acute (BmRNAa_SREBP) and 
chronic (BmRNAc_SREBP) studies were either ﬁ  xed 
to 1 or estimated in the modeling.
The FAT and GPAT mRNA (mRNA) versus time 
proﬁ  les were described as:
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where IC50_DR(N) represents the concentration of 
DR(N) at which the production rate of mRNA is 
reduced to 50% of its baseline level and γSREBP is 
a power term representing the stimulatory efﬁ  -
ciency on gene transcription by SREBP-1c. FAT 
and GPAT mRNA data from both i.v. bolus and 
infusion studies were simultaneously fitted. 
Assuming steady-state at time zero, Eq. 25 allows 
calculation of:
  k
k
TC
sm
dm
n
SREBP _
_
()
= 0 γ  (26)
where  TCn
0 is the baseline value of TCn and is 
ﬁ  xed as 1.
Figure 4. Pharmacodynamic/pharmacogenomic model for CS effects on gene expression of SREBP-1c and its regulated genes. Symbols 
and differential equations are deﬁ  ned in Eq. 19 to 24 and Table 4.149
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Endothelin-1 (ET-1)
It has been found that ET-1 may enhance nitric 
oxide production via its receptor located in endo-
thelial cells (Namiki et al. 1992). Conversely, nitric 
oxide can inhibit ET-1 synthesis in different cell 
types (Takada et al. 1996). A model is proposed 
assuming there is a feedback loop regulating the 
production of ET-1 (Fig. 5). The equations describ-
ing ET-1 mRNA (mRNA) time proﬁ  le following 
MPL treatment are:
 
dmRNA
dt
k
SD R N
TC
IC TC
k
sm
DR N
n
ET n
dm
=
×+ ⋅
×−
+
⎛
⎝
⎜
⎞
⎠
⎟ −
_
()
_
_
(( ) ) 1
1
50 1
⋅⋅ mRNA
 (27)
 
dTC
dt
km R N A T C e
1
1 =⋅ − ()  (28)
 
dTC
dt
kT C T C
n
en n =⋅ − − (( ) ) 1
γ  (29)
where gene transcription is dependent on DR(N) 
with a linear stimulatory coefﬁ  cient (SDR(N)). The 
IC50_ET1 represents the concentration of TCn at which 
the production rate of mRNA is reduced to 50% of 
its baseline level under the inhibition of itself and γ 
is a power term describing the ampliﬁ  cation effect 
during the transit steps. Assuming steady-state at 
time zero, Eq. 27 allows calculation of:
  k
kI C T C
IC
sm
dm E T n
ET
_
__
_
()
=
⋅+ 50 1
0
50 1
 (30)
where TCn
0 is the baseline value of TCn and is ﬁ  xed 
as 1.
Data analysis
The gene array data were obtained from a ‘giant 
rat’ study design reﬂ  ecting naïve pooling of data 
from a group of animals (Sun et al. 1999; Ramak-
rishnan et al. 2002). Microarray data from both i.v. 
bolus and infusion studies were simultaneously 
ﬁ  tted. Since acute and infusion data were obtained 
from two different types of chips, a scaling factor 
(SF) was incorporated in the modeling to account 
for the different sensitivity of two chips to the same 
gene expression changes. The output functions of 
mRNA in acute (YA(t)) and chronic (YC(t)) studies 
were expressed as:
  Yt m R N At AA () () =  (31)
  Yt m R N At CC
SF () ( () ) =  (32)
where mRNAA(t) and mRNAC(t) represent mRNA 
expression at time t in acute and chronic studies. 
Since relative sensitivity was considered in the 
present report, the scaling factor was only added 
to the chronic data.
Assuming that the errors from the observed and 
predicted responses are normally distributed, the 
ADAPT II program (D’Argenio and Schumitzky, 
1997) with the maximum likelihood method was 
applied for all ﬁ  ttings. The following variance 
model was used:
  VV t Y t ii = () =+ ⋅ () ( ) θσ σ σ θ ,, , 12
2  (33)
Figure 5. Pharmacodynamic/pharmacogenomic model for CS effects on gene expression of ET-1. Symbols and differential equations are 
deﬁ  ned in Eq. 25 to 28 and Table 5.150
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where Vi is the variance of the response at the ith 
time point, ti is the actual time at the ith time point, 
θ represents the systemic parameter vector for the 
respective pharmacodynamic (PD) model, σ is 
deﬁ  ned as the vector of variance parameters for the 
model, Y(θ, ti) is the predicted response value at 
time ti from the model. Variance parameters σ1 and 
σ2 were estimated along with model parameters 
during ﬁ  ttings. Mean data from 3 or 4 animals at 
each time point were used in ﬁ  tting the models. The 
goodness-of-ﬁ  t criteria included visual inspection 
of the ﬁ  tted curves, estimator criterion value, sum 
of squared residuals, Akaike information criterion, 
Schwartz criterion, and coefﬁ  cients of variation 
(CV) of the estimated parameters.
Results
Drug kinetics
Plasma concentrations of MPL following i.v. bolus 
were described by a two-compartment model. The 
MPL PK proﬁ  le following drug infusion was gen-
erated using the reported parameters (Ramakrish-
nan et al. 2002) (Fig. 6). The estimated and ﬁ  xed 
parameters are summarized in Table 1.
Receptor dynamics
The integrated receptor-gene mediated model 
adequately captured both GR mRNA and cytosolic 
free receptor data following acute MPL treatment. 
The proﬁ  les of GR mRNA and cytosolic GR density 
versus time and the least-squares ﬁ  tted curves are 
shown in Figure 7. The GR mRNA concentration 
drops from the baseline level to the trough in 10 h 
and then slowly returns to the baseline. Free GR 
disappears quickly from cytosol and is not detect-
able between 0.5 to 2 h after dosing. The recovery 
of GR density shows an initial rapid phase between 
2 to 20 h which is responsible for 40% of recovery 
and a later slower phase persisting until 72 h. 
Simulations of major components in the receptor 
dynamic model (data not shown) suggest that 
DR(N) increases after MPL treatment and reaches 
a peak at 0.1 h and declines thereafter. The DR(N) 
disappears 10 h after dosing. In the present report, 
the simulated proﬁ  le of DR(N) served as the driv-
ing force for stimulation or inhibition of down-
stream gene transcription. Since receptor mRNA 
and receptor density data were absent for the infu-
sion study, the resultant parameters from the acute 
study were used to simulate receptor dynamics in 
muscle during the infusion and receptor dynamics 
were ﬁ  xed in the subsequent gene regulation mod-
eling (Fig. 7). These simulations suggest that both 
receptor mRNA and free cytosolic receptor are 
maintained at very low levels during long-term 
MPL infusion, which is consistent with our mea-
surements in the liver from these same animals 
(Ramakrishnan et al. 2002).
The ﬁ  xed and estimated parameters of the recep-
tor dynamics model are listed in Table 1. This 
model is over-parameterized leading to the neces-
sity of ﬁ  xing the kT value, which was derived from 
in vitro literature data. Translocation of GR from 
cytoplasm to nucleus is complete in 10 minutes 
when cells are incubated with 10 nM dexamethasone 
Figure 6. MPL pharmacokinetics following 50 mg/kg MPL i.v. bolus administration and 0.3 mg/kg/h 7-day infusion. Chronic PK proﬁ  le was 
simulated (Eq. 1 and 2) using pharmacokinetic parameters listed in Table 1. Original plasma MPL concentrations were obtained from Sun 
et al. (Sun et al. 1999).151
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(Htun et al. 1996). Dexamethasone at 10
−6 M leads 
to complete translocation in 0.1 h (Hache et al. 
1999). However, the translocation rate in those in 
vitro studies is determined by both receptor-steroid 
binding and ﬁ  rst-order cytosol-nucleus transloca-
tion. According to literature data, the ﬁ  rst-order 
translocation rate kT has to be higher than 35 h
−1. 
Our kT was ﬁ  xed to 90 h
−1 in the modeling of recep-
tor dynamics. The GRmRNA
0  and GR
0 were estimated 
at 2.99 fmol/g tissue and 65.3 fmol/mg protein. 
Figure 7. Time courses of GR mRNA and free receptor density in ADX rat muscle following 50 mg/kg MPL i.v. bolus and 0.3 mg/kg/h infusion 
treatments. Data points are observed values and error bars are standard deviations at each time point. Solid lines are the ﬁ  tted curves for 
acute study or simulated curves for chronic study. Chronic proﬁ  les were simulated using parameters listed in Table 1. Original GR mRNA 
and cytosolic GR density data were obtained from Sun et al. (Sun et al. 1999).
Table 1. Fixed and estimated pharmacokinetic and receptor dynamic parameters.
Parameter (unit) Deﬁ  nition Value CV%
Pharmacokinetics
CL (l/h/kg) Clearance 2.86
a/5.61
b 9
a–b
Vp (l/kg) Central volume of distribution 0.70
a/0.82
b 39
a–b
k12 (1/h) Distribution rate constant 4.33
a/0.32
b 47
a–b
k21 (1/h) Distribution rate constant 3.09
a/0.68
b 15
a–b
Receptor dynamics
ks–Rm (fmol/g muscle/h) GR mRNA synthesis rate constant 0.416 –
c
IC50–Rm (fmol/mg protein) Inhibition constant 0.911 126
kd–Rm (1/h) GR mRNA degradation rate constant 0.139 18
kon (1/nmol/h) Association rate constant 0.00269 73
kre (1/h) DR(N) overall loss rate constant 0.618 50
Rf Recycling fraction 0.720 12
kd–R (1/h) GR degradation rate constant 0.0356 27
kT (1/h) Translocation rate constant 90 –
ks–R (fmol/mg/(fmol mRNA/g)/h) GR synthesis rate constant 0.777 –
c
GRmRNA
0  (fmol/g muscle) Baseline GR mRNA 2.99 8
GR
0 (fmol/mg protein) Baseline GR 65.3 3
a Estimated from i.v. bolus data.
b Fixed for infusion data.
c Secondary parameters.152
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The estimated GR mRNA and GR degradation rates 
yield half-lives of GR mRNA of 5.0 h and protein 
of 19.5 h. The IC50_Rm was estimated at 0.911 
fmol/mg protein, suggesting GR mRNA transcrip-
tion is sensitive to the inhibition by steroid treat-
ment. About 72% of DR(N) is recycled back into 
cytosol while the rest is degradated during one 
cytosol-nucleus cycle.
IL6R and IRS-1
Simultaneous modeling using a basic indirect 
response model with direct stimulation by DR(N) 
well captured IL-6 receptor 1 mRNA following 
both i.v. bolus and infusion treatments. Figure 8 
shows the normalized data from gene arrays and 
the ﬁ  tted curves. Following 50 mg/kg MPL treat-
ment, expression of IL-6R1 mRNA exhibits a 
similar pattern as tyrosine aminotransferase (TAT) 
in the liver (Sun et al. 1998; Jin et al. 2003). 
It shows a rapid induction of expression which 
peaked at 5.5 h following drug treatment. The en-
hanced expression lasts for about 20 h and thereafter 
maintains baseline level. Compared to DR(N), the 
induction of IL-6 receptor mRNA reveals a 3 h time 
delay. Following the 0.3 mg/kg/h infusion, IL-6 
expression is increased and maintained at a high 
level throughout the long-term treatment period. 
Table 2 lists the estimated PD parameters and their 
precision. The estimated kd_IL6R1m yields a degrada-
tion half-life of 2.26 h. The stimulatory constant 
SC50_IL6R1m was estimated at 1.09 fmol/mg protein, 
suggesting high sensitivity to MPL action.
The transcription of IRS-1 was described by a 
more complex regulation with inhibitory effects 
derived directly by DR(N) and indirectly through 
IL-6 receptor. The proposed PK/PD model 
reasonably captured the down-regulation of IRS-1 
message by MPL administration (Fig. 8). In the 
acute study, the expression proﬁ  le exhibits two 
inhibitory phases. The ﬁ  rst decline occurs imme-
diately after drug treatment and reaches the nadir 
around 5.5 to 6 h. This phase was successfully 
described by direct inhibition by DR(N) under the 
assumption that the drug-receptor complex 
represses the transcription of IRS-1 mRNA. It 
returns to a value which is close to baseline by 
12 h. The second decline phase starts at 18 h and 
exhibits a much slower decrease with a trough at 
40 h. The second phase was described by aug-
mented inhibition of IRS-1 mRNA transcription 
by the IL-6 receptor. Comparing the curves of 
IRS-1 and IL-6 receptor 1 mRNA reveals a delay 
time of 30 h between the second decline of IRS-1 
and its driving force. This is consistent with a 
previous report that reduction of IRS-1 mRNA is 
seen 24 h following IL-6 treatment in adipose cells 
(Rotter et al. 2003). The long time delay necessi-
tated the utilization of multiple transit compart-
ments between the driving force and the regulated 
gene expression. Five transit compartments were 
adequate to capture the curve and give reasonable 
parameter estimates and CV values (Table 2). In 
the infusion study, IRS-1 mRNA declines follow-
ing drug treatment and reaches a steady-state 
throughout the 7-day study.
Figure 8. Time courses of IL-6 receptor 1 and IRS-1 gene expression in ADX rats following bolus and infusion MPL treatments. Symbols 
are the mean gene array data, bars are standard deviations, and solid lines are ﬁ  tted curves (Eq. 10–12).153
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Table 2. Estimated PD/PG parameters for IL-6 receptor 1 and IRS-1.
Parameter (unit)  Deﬁ  nition  Estimate  CV%
IL-6 receptor 1
kd–IL6R1m (h
-1) mRNA degradation rate constant 0.306 38
Smax–IL6R1m Maximum stimulation by DR(N) 3.05 23
SC50–IL6R1m (fmol/mg protein) Stimulatory constant by DR(N) 1.09 107
SF Scaling factor 0.857 10
IRS-1
ke (h
-1) Transduction rate constant 0.144 18
kd–m (h
-1) mRNA degradation rate constant 0.313 13
IC50–DR(N) (fmol/mg protein) Inhibition constant by DR(N) 5.95 24
IC50–IL6R1 Inhibition constant by IL-6 receptor 1 0.196 182
SF Scaling factor 0.305 18
N Number of transit compartments 5 –
MyoD, UCP3 and PDK4
MyoD mRNA expression proﬁ  les following i.v. bolus 
and infusion treatments were well captured by the 
dynamic model assuming a direct inhibition of 
transcription by DR(N) and another inhibitory effect 
from the biosignal (Fig. 9). In the acute study, MyoD 
mRNA exhibits a sharp decline immediately follow-
ing MPL treatment. The trough occurs at 4 h, only 2 
h after the peak of DR(N). Following infusion, MyoD 
transcription quickly declined and reached the ﬁ  rst 
trough at 6 h and was reduced to almost zero. Then 
it increased with a slow slope and regained 40% of 
its basal level at 36 h and then decreased thereafter. 
The second decline is described by the inhibitory 
effect from the biosignal. The estimated parameters 
are listed in Table 3. A high kd_MyoDm yields a short 
degradation half-life of 0.495 h
−1 and is consistent 
with the rapid decline and short time delay. The 
parameters were estimated with reasonable precision 
with most CVs below 30% (Table 3).
The proposed model was able to describe the 
time proﬁ  les of both PDK4 and two probe sets for 
UCP3. The original data and the ﬁ  tted curves are 
shown in Figure 9. In the acute study, both UCP3 and 
PDK4 mRNA reveal a sharp enhancement of produc-
tion which is well captured by the direct stimulation 
of DR(N). The peaks occur at 5 h after drug admin-
istration. All three probe sets return to baseline by 15 
h and thereafter continuously decline and reach 
steady-states after 18 h. The inhibitory phases were 
adequately captured by the reduced activation by 
MyoD. Following drug infusion, all three probes 
exhibit only enhanced transcription without the 
inhibitory phase. One transit compartment was ade-
quate for modeling of both UCP3 and PDK4. The 
degradation half-life of UCP3 was estimated between 
3.6 and 4.4 h while that of PDK4 was 2.1 h. Moder-
ate stimulatory coefficients (SDR(N)) around 0.15 
(fmol/mg protein)
−1 were obtained for UCP3. For 
PDK4, two parameters Smax and SC50 were required 
to capture both acute and chronic proﬁ  les simultane-
ously. The estimated low SC50 suggests high efﬁ  -
ciency of the stimulatory effect and also justiﬁ  es the 
requirement of using both parameters. Two probe sets 
for UCP3 exhibit similar expression versus time pat-
terns and yield similar parameter estimates, suggest-
ing good reproducibility of the oligonucleotide 
microarray assay. Most parameters were estimated 
with CV below 40% (Table 3).
SREBP-1c, FAT, and GPAT
The SREBP-1c mRNA time proﬁ  les were captured 
by the joint inhibitory effects on the transcription 
directly by DR(N) and indirectly by an unknown 
intermediate biosignal (Fig. 10). The expression of 
SREBP-1c is down-regulated after MPL treatment. 
Following its trough at 4 h in the acute study, it 
returned to baseline in a biphasic pattern with an 
initial fast return phase and a later shallow phase. 
A similar pattern was shown in the chronic study. 
The biphasic change suggests that two driving 
forces probably are involved. The mediator BS was 
incorporated in the model based on the assumption 154
Yao et al
Gene Regulation and Systems Biology 2008:2 
that the absolute change of a regulator level by 
DR(N) may elicit an inhibitory effect on the tran-
scription rate of SREBP-1c mRNA (Jin et al. 2003). 
The estimated kBS of 0.0436 h
−1 yields a relatively 
long mean transit time of 23 h, which is consistent 
with the prolonged repression of SREBP-1c until 
72 h. The degradation half-life of SREBP-1c mRNA 
was ﬁ  xed to 1 to obviate over-parameterization. 
Both DR(N) and the biosignal display moderate 
inhibition on SREBP-1c transcription with an 
IC50_SREBP of 66.7 fmol/mg protein and an IC50_BS 
of 12.4 fmol/mg protein. The estimated parameters 
are listed in Table 4. The dynamics of SREBP-1c 
served as the driving force for FAT and GPAT and 
was ﬁ  xed in the following modeling.
Simultaneous modeling using the proposed 
model well captured the expression of FAT and 
GPAT (Fig. 10). They were down-regulated follow-
ing 50 mg/kg MPL with the ﬁ  rst troughs between 
5.5 to 8 h. The initial declines were well described 
by the direct inhibition of gene transcription by 
DR(N) for both genes. The suppressed activation of 
SREBP-1c on GPAT leads to a second decline while 
the same regulatory mechanism leads to a prolonged 
return phase for FAT. Following 7-day MPL infu-
sion, the ﬁ  rst trough occurs around 20 h for both 
genes. Similarly to what was seen in the acute study, 
a second decline occurs only with GPAT but not 
with FAT. The degradation rate constants of the 
messages are around 0.16 h
−1. The DR(N) has a 
moderate to high inhibitory effect on the gene 
transcription with the IC50_DR(N) between 2.27 to 
9.97 fmol/mg protein. GPAT has a higher γSREBP 
than that of FAT which may explain the stronger 
suppression of GPAT message under the control of 
SREBP-1c. Two to four transit compartments were 
required to ﬁ  t the data. The estimated parameters 
and their precisions are shown in Table 4.
Figure 9. Time courses of MyoD and its regulated genes UCP3 (represented by two probe sets) and PDK4 in ADX rats following bolus and 
infusion MPL treatments. Symbols and lines are deﬁ  ned as in Figure 8.155
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ET-1
The time proﬁ  les of ET-1 mRNA following both 
acute and chronic treatments were captured by the 
proposed model (Fig. 11). Immediately following 
50 mg/kg MPL dosing, it exhibits a sharp induction 
peak at 2–3 h and then decreases below baseline after 
12 h. The abrupt stimulation and the short time shift 
between ET-1 mRNA and DR(N) can be explained 
by a fast mRNA degradation rate constant of 
0.958 h
−1, yielding a half-life of 0.723 h. A short 
half-life might be necessary to obtain quickly 
induced or reduced effects on vasoconstriction. 
The power parameter γ was estimated at 8.23, 
representing a considerable magnifying effect during 
the signaling transduction steps. A model with 8 
transit compartments was selected based on visual 
inspection of the ﬁ  tted curve and other model selec-
tion criteria. Following infusion, the change of ET-1 
mRNA expression was ﬂ  at. This apparent lack of 
response of ET-1 to chronic infusion might be due 
to low sensitivity of the probe set on genechip 230A 
to the change of mRNA level, which can be seen 
from the estimated SF of 0.118. Table 5 summarizes 
the estimated parameters and their precision.
Discussion
Insulin resistance is a pathological state where 
peripheral tissues, particularly skeletal muscle, fail 
to respond to circulating insulin (Gual et al. 2005). 
One of the earliest abnormalities observed in skeletal 
muscle is the reduced insulin-induced uptake of 
glucose. The 50 mg/kg MPL i.v. injection in ADX 
rats leads to a transient increase in the plasma glucose 
concentration that begins about 2 h and lasts for 9 h 
(Almon et al. 2005b). Plasma insulin concentrations 
are increased between 2 to 48 h after dosing, prob-
ably due to increased plasma glucose levels .
The development and progression of insulin 
resistance is not mediated by a single gene. Abnor-
malities in multiple molecules and tissues are 
involved in the pathogenesis of the disease. In such 
situations, research focused on single mediators may 
distort the true underlying molecular and cellular 
mechanisms and inadequately reveal overall 
regulatory factors and pathways. By analyzing joint 
temporal responses of many genes simultaneously, 
it should be possible to gain a better understanding 
of regulatory pathways and their contributions to 
this complex pathology. By using two different dos-
ing regimens in the time series format, we not only 
obtained joint conﬁ  rmation but also augmented the 
elucidation of underlying mechanisms of regulation. 
In the present report we describe the development 
of four models that encompass six genes associated 
with insulin resistance. These models include both 
direct effects of CS on the genes as well as indirect 
effects due to the effects of CS on other transcription 
factors such as MyoD and SREBP-1c.
The ﬁ  rst model describes the regulation of IRS-1 
which plays a central role in insulin signaling. IRS-
1 is phosphorylated in response to insulin, insulin 
like growth factor-1, and cytokines and is preferen-
tially involved in the metabolic actions of insulin 
(Gual et al. 2005). A decline of IRS-1 amount or 
function has been linked to decreased glucose uptake 
in insulin resistant animal models and type II diabetic 
patients (Sesti et al. 2001; Smith, 2002).
Strong correlations between local and circulating 
proinﬂ  ammatory cytokines and insulin resistance 
have been reported (Senn et al. 2002). Among them, 
IL-6 has the strongest correlation with insulin 
Figure 10. Time courses of SREBP-1c and its regulated genes FAT and GPAT in ADX rats following bolus and infusion MPL treatments. 
Symbols and lines are deﬁ  ned as in Figure 8.157
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resistance and type II diabetes. In liver, IL-6 
elevates hepatic glucose output and increases blood 
glucose by interfering with insulin-induced kinase 
cascades such as tyrosine phosphorylation of IRS-1 
(Senn et al. 2002). Adipose tissue and muscle, two 
peripheral tissues that are responsible for glucose 
disposal, are important sites of IL-6 production 
(Senn et al. 2002). Thus it is possible that IL-6 
produced in these tissues may act at the local site 
and interfere with insulin-induced signaling. It has 
been found that IL-6 exerts long-term inhibitory 
effects on the transcription of IRS-1 (Rotter et al. 
2003). Although it is well accepted that CS also 
inhibit the expression of many cytokines including 
IL-6 in inﬂ  ammation, it is not known if CS exhib-
its similar effects in healthy animals. In our studies, 
the expression of IL-6 mRNA in muscle did not 
show signiﬁ  cant change. However, we observed a 
signiﬁ  cant up-regulation of IL-6 receptor type 1 
transcription. Thus it is reasonable to assume that 
increased expression of IL-6 receptor potentially 
enhances muscle sensitivity to IL-6 and augments 
the inhibitory effect of IL-6 on IRS-1 transcription.
The second model describes the regulation of 
two nuclear encoded mitochondrial genes that have 
been associated with insulin resistance, UCP3 and 
PDK4. Uncoupling proteins are a family of trans-
porters that localize in the mitochondrial inner 
membrane and dissipate the transmembrane poten-
tial by transporting protons from the inter-mem-
brane space back into the matrix (Garvey, 2003). 
UCP3 exhibits limited tissue-speciﬁ  c expression 
conﬁ  ned to skeletal muscle in humans. Accumulat-
ing evidence indicates that in skeletal muscle, UCP3 
contributes to lipid uptake by mitochondria rather 
than uncoupling oxidative phosphorylation (Gar-
vey, 2003). PDK4 is an enzyme that inactivates the 
mitochondrial pyruvate dehydrogenase complex. 
It thus reduces glucose utilization by skeletal 
muscle, preventing pyruvate (the product of gly-
colysis) from being used by the mitochondria 
(Sugden, 2003). The PDK4 gene is preferentially 
expressed in skeletal muscle. Both genes are 
associated with enhanced fatty acid oxidation, thus 
probably are involved in the preferential fuel utili-
zation of lipids instead of glucose in insulin resis-
tance states. Enhanced expressions of both UCP3 
and PDK4 in skeletal muscle have been associated 
with obesity and type II diabetes in humans (Bao 
et al. 1998; Sugden and Holness, 2002).
The bi-directional proﬁ  les of UCP3 and PDK4 
mRNA expression following MPL treatment sug-
gest that more than one mediator is involved in the 
regulatory pathways. The down-regulation of 
MyoD by CS that we observed in our studies along 
with literature searches and examination of the 
promoter regions of the two genes indicate that 
Table 5. Estimated PD/PG parameters for ET-1.
Parameter (unit) Deﬁ  nition Estimate CV%
kd_m (h
−1) mRNA degradation rate constant 0.958 17
SDR(N) (fmol/mg protein)
−1 Stimulatory coefﬁ  cient by DR(N) 0.0313 9
ke (h
−1) Transduction rate constant 0.343 7
IC50_ET1 Inhibition constant by ET-1 11.1 131
γ Ampliﬁ  cation power constant 8.23 50
SF Scaling factor 0.118 116
N Number of transit compartments 8 –
Figure 11. Time course of ET-1 gene expression in ADX rats follow-
ing. Bolus and infusion MPL treatments. Symbols and lines are 
deﬁ  ned as in Figure 8.159
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myogenic factor MyoD might be involved in a 
complex signaling network (Solanes et al. 2000; 
Solanes et al. 2003). MyoD belongs to the basic 
helix-loop-helix family of DNA-binding transcrip-
tion factors. It is a master regulator of muscle 
lineage differentiation and is responsible for the 
preferential expression of skeletal muscle-speciﬁ  c 
genes (Solanes et al. 2000). At least two phyloge-
netically conserved MyoD responsive sites were 
found in the promoter regions of both genes. MyoD 
is required not only for UCP3 promoter activity 
but also for its sensitivity to activation by other 
ligands (Solanes et al. 2000; Solanes et al. 2003). 
Additionally, the muscle-preferential expression 
of UCP3 and PDK4 also supports an essential role 
of MyoD in transcriptional regulation.
The third model describes the regulation of the 
expression of two genes involved in lipid metabo-
lism in skeletal muscle. The ﬁ  rst is FAT, also called 
CD36, which is a membrane protein that facilitates 
fatty acid uptake and use by skeletal muscle 
(Heron-Milhavet et al. 2004). Muscle-speciﬁ  c over 
expression of FAT reverses insulin resistance and 
diabetes in animal models (Heron-Milhavet et al. 
2004). The second is GPAT which catalyzes the 
initial and committed step in the biosynthesis of 
triglycerides and phospholipids (Ericsson et al. 
1997). Expression of these genes indicates a shift 
of energy consumption in the skeletal muscle from 
glycolysis towards β-oxidation.
SREBP-1c is a transcription factor of the basic 
helix-loop-helix/leucine zipper family. It controls 
expression of genes which are related to adipogenesis 
and fatty acid metabolism as well as cholesterol 
metabolism (Nguyen et al. 2000). SREBP-1c is 
transcriptionally induced by insulin and its 
enhanced expression mediates the transcriptional 
effects of insulin in skeletal muscle (Guillet-Deniau 
et al. 2002). It has been observed that over-expres-
sion of SREBP-1c mimics the effects of insulin 
such as stimulation of glycolytic and lipogenic 
enzymes. It exerts a pivotal role in long-term 
muscle insulin sensitivity. The prolonged returning 
of FAT expression and the second trough of GPAT 
at 48 h raises the possibility that at least one inter-
mediate biosignal is involved. Both genes are 
transcriptionally induced by SREBP-1c (Ericsson 
et al. 1997; Ntambi, 1999; Nguyen et al. 2000; 
Almon et al. 2005b). The addition of SREBP-1c 
as an intermediate driving force was able to capture 
the time proﬁ  les of FAT and GPAT following both 
acute and infusion dosing regimens.
ET-1 is a potent vasoconstrictor. It has been 
observed that many organs such as heart, lung and 
skeletal muscles synthesize ET-1, which may act 
locally to regulate blood ﬂ  ow (Sakurai et al. 1991; 
Guo et al. 1998). The ET-1 detected in this study 
might be muscle in origin, endothelial cell in origin, 
or both. Elevated muscle ET-1 may reduce blood ﬂ  ow 
to the musculature and thus reduce glucose disposal 
in skeletal muscle (Santure et al. 2002). Reciprocal 
regulation of ET-1 and nitric oxide, a vasodilator have 
been demonstrated and summarized by Rossi et al. 
(Rossi et al. 2001). The production of nitric oxide is 
activated by ET-1 while the elevated nitric oxide level 
is able to inhibit ET-1 synthesis (Namiki et al. 1992; 
Takada et al. 1996). This forms a negative feedback 
loop which may offer an oscillatory feature to ET-1 
expression pattern once it is induced or inhibited by 
drug treatment. The ﬁ  tted curve in our acute study 
exhibited a ﬂ  uctuation around the baseline. Other 
studies demonstrate that ET-1 also exhibits similar 
time proﬁ  les following interleukin-1β and lipopoly-
saccharide treatments in human endothelial cells with 
an initial up-regulation and a later down-regulation 
at 24 h (Zhao et al. 2001; Zhao et al. 2003). Those 
results suggest that this oscillatory feature of ET-1 is 
not speciﬁ  c to CS treatment. ET-1 expression follow-
ing drug infusion did not show signiﬁ  cant change, 
possibly due to reduced probe set sensitivity in the 
chip used for the chronic study.
In the present report, most modeled time proﬁ  les 
feature long time delays between the intermediate 
biosignal and the regulated changes. One or more 
transit compartments were incorporated in the 
models to account for the delay. Following drug 
treatment, the resultant changes in message have 
to translate into protein changes before downstream 
regulatory steps can continue. Other steps such as 
translocation in or out of the nucleus or induction 
of other mediators might also be involved.
Time series studies of gene expression following 
CS treatment shows that many genes such as 
UCP3, PDK4, and ET-1 exhibit both induction and 
suppression depending on time. Evaluation of drug 
effects at a single time point may not reveal the 
overall effects of the drug. In such situations, time 
series design and mathematical modeling provide 
a useful approach to explore the diverse effects at 
different times and the actual or potential underly-
ing mechanisms.
It is interesting to see that genes with common 
regulators such as UCP3 and PDK4 display com-
parable expression versus time patterns. This may 160
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suggest shared or similar signaling pathways 
associated with the regulation of these genes. 
However, genes regulated by common mediators 
may also exhibit distinct patterns, possibly due to 
diverse signaling pathways or differences in 
parameter values.
The sampling time points in the acute studies 
were selected based on prior knowledge of the 
CS-induced TAT expression proﬁ  le following the 
same acute dosing regimen. The expression of TAT 
reaches a peak at 6 h following acute dosing and 
returns to baseline at 18 h (Sun et al. 1998). Such 
a sampling strategy well characterized the earlier 
expression changes of most genes which are rap-
idly induced or repressed by steroids. However, 
the sparse sampling after 18 h leads to lack of 
information to characterize slower, more complex 
signaling events, especially for those genes that 
are controlled by multiple regulatory cascades. 
Two genes involved in fatty acid metabolism, 
glycerol-3-phosphate dehydrogenase (GPDH) and 
stearyl-CoA desaturase 2 (SCD2) also exhibited a 
second decline at 48 h following MPL (Almon 
et al. 2005b). Both GPDH and SCD2 are activated 
by the master transcription factor SREBP-1c 
(Nguyen et al. 2000). However, lack of information 
after 30 h excluded the possibility of using complex 
models to capture their proﬁ  les. The initial sam-
pling time point in the chronic study (6 hours) was 
selected to allow the drug to reach equilibrium in 
circulation. This may have impaired our ability to 
capture initial dynamics. However, the responses 
to two dosing regimens together clearly augment 
each other.
A scaling factor was used in modeling of all 
genes when both acute and chronic data were 
simultaneously ﬁ  tted. Two different chips U34A 
and 230A were utilized for acute and chronic stud-
ies. The probe sets representing the same gene on 
these two chips differ in their nucleotide length 
and sequences. This may lead to different 
hybridization efﬁ  ciencies and therefore different 
relative sensitivities to gene expression changes. 
In the modeling, a power scaling factor was incor-
porated to account for these differences.
This study was limited by the availability of 
genes on the chips. The assay sensitivity and our 
data analysis methods also restricted the number of 
genes that were identiﬁ  ed by this approach, espe-
cially for low abundance message or suppressed 
genes. Some important regulators and biomarkers 
may not be included. In addition to its transcriptional 
regulatory effects, CS also exerts effects by affecting 
protein synthesis or interaction with other proteins, 
which cannot be detected in the current study.
In the present study we used results from two gene 
array time series to develop dynamic models for the 
regulation of several genes associated with insulin 
resistance in skeletal muscle. In order to begin to 
understand complex polygenic phenomena such as 
insulin resistance, it necessary to develop quantita-
tive, experimentally testable hypotheses such as the 
dynamic models presented in this report.
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